keyword
MENU ▼
Read by QxMD icon Read
search

placebo Response in Antipsychotic Clinical Trials A Meta-analysis

keyword
https://www.readbyqxmd.com/read/29368813/selective-noradrenaline-reuptake-inhibitors-for-schizophrenia
#1
REVIEW
Paul R L Matthews, Jamie Horder, Michael Pearce
BACKGROUND: Schizophrenia is frequently a chronic and disabling illness with a heterogeneous range of symptoms. The positive symptoms usually respond to antipsychotics but the cognitive and negative symptoms of schizophrenia are difficult to treat with conventional antipsychotics and significantly impact on quality of life and social outcomes. Selective noradrenaline reuptake inhibitors (NRIs) increase prefrontal dopamine and noradrenaline levels without significantly affecting subcortical dopamine levels, making them an attractive candidate for treating cognitive and negative symptoms...
January 25, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29338576/effect-of-clinical-response-to-active-drugs-and-placebo-on-antipsychotics-and-mood-stabilizers-relative-efficacy-for-bipolar-depression-and-mania-a-meta-regression-analysis
#2
Francesco Bartoli, Massimo Clerici, Carmen Di Brita, Ilaria Riboldi, Cristina Crocamo, Giuseppe Carrà
BACKGROUND: Randomised placebo-controlled trials investigating treatments for bipolar disorder have been hampered by wide variations of active drugs and placebo clinical response rates. It is important to estimate whether the active drug or placebo response has a greater influence in determining the relative efficacy of drugs for psychosis (antipsychotics) and relapse prevention (mood stabilisers) for bipolar depression and mania. METHODS: We identified 53 randomised, placebo-controlled trials assessing antipsychotic or mood stabiliser monotherapy ('active drugs') for bipolar depression or mania...
April 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29144549/zuclopenthixol-dihydrochloride-for-schizophrenia
#3
REVIEW
Edward J Bryan, Marie Ann Purcell, Ajit Kumar
BACKGROUND: Oral zuclopenthixol dihydrochloride (Clopixol) is an anti-psychotic treatment for people with psychotic symptoms, especially those with schizophrenia. It is associated with neuroleptic malignant syndrome, a prolongation of the QTc interval, extra-pyramidal reactions, venous thromboembolism and may modify insulin and glucose responses. OBJECTIVES: To determine the effects of zuclopenthixol dihydrochloride for treatment of schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (latest search 09 June 2015)...
November 16, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29048739/pharmacotherapy-for-social-anxiety-disorder-sand
#4
REVIEW
Taryn Williams, Coenraad J Hattingh, Catherine M Kariuki, Sean A Tromp, Anton J van Balkom, Jonathan C Ipser, Dan J Stein
BACKGROUND: Recognition is growing that social anxiety disorder (SAnD) is a chronic and disabling disorder, and data from early trials demonstrate that medication may be effective in its treatment. This systematic review is an update of an earlier review of pharmacotherapy of SAnD. OBJECTIVES: To assess the effects of pharmacotherapy for social anxiety disorder in adults and identify which factors (methodological or clinical) predict response to treatment. SEARCH METHODS: We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR-Studies and CCMDCTR-References) to 17 August 2015...
October 19, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28712616/aripiprazole-lauroxil-compared-with-paliperidone-palmitate-in-patients-with-schizophrenia-an-indirect-treatment-comparison
#5
REVIEW
Chris Cameron, Jacqueline Zummo, Dharmik N Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for treatment of schizophrenia on the basis of a large-scale trial of two doses of AL versus placebo. There are no direct-comparison studies with paliperidone palmitate (PP; long-acting antipsychotic used most often in acute settings) for the acute psychotic episode. OBJECTIVES: To indirectly compare efficacy and safety of the pivotal AL study with all PP studies meeting indirect comparison criteria...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28553116/comparative-efficacy-and-safety-of-antipsychotics-in-the-treatment-of-schizophrenia-a-network-meta-analysis-in-a-japanese-population
#6
Taro Kishi, Toshikazu Ikuta, Shinji Matsunaga, Yuki Matsuda, Kazuto Oya, Nakao Iwata
BACKGROUND: The relative efficacy and tolerability of antipsychotics for schizophrenia are considerably well studied. This study aimed to examine whether previous findings could be replicated in a genetically distinct and homogenous group (ie, Japanese patients with schizophrenia) and whether previous findings could be extended to a broader range of antipsychotics with previously unclear relative efficacy and tolerability. METHODS: Bayesian network meta-analysis was performed in which randomized trials comparing any of the following interventions were included: second-generation antipsychotics, haloperidol, or placebo...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28264635/lurasidone-compared-to-other-atypical-antipsychotic-monotherapies-for-bipolar-depression-a-systematic-review-and-network-meta-analysis
#7
Michael Ostacher, Daisy Ng-Mak, Pankaj Patel, Dionysios Ntais, Max Schlueter, Antony Loebel
OBJECTIVES: To assess the efficacy and tolerability of lurasidone versus other atypical antipsychotic monotherapy agents in patients with bipolar depression, using a Bayesian network meta-analysis. METHODS: Fourteen randomised clinical trials (6221 patients) of lurasidone, quetiapine (extended release and immediate release), aripiprazole, olanzapine, and ziprasidone for bipolar depression were included. Efficacy assessments included change in the Montgomery-Åsberg Depression Rating Scale (MADRS), rates of response (≥50% improvement in MADRS) and remission (MADRS ≤12 at study endpoint), and change in the Clinical Global Impressions-Bipolar Disorder-Severity (CGI-BP-S) scale...
March 7, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28100425/safety-and-efficacy-of-adjunctive-second-generation-antidepressant-therapy-with-a-mood-stabiliser-or-an-atypical-antipsychotic-in-acute-bipolar-depression-a-systematic-review-and-meta-analysis-of-randomised-placebo-controlled-trials
#8
Alexander McGirr, Paul A Vöhringer, S Nassir Ghaemi, Raymond W Lam, Lakshmi N Yatham
BACKGROUND: Although mania and hypomania define bipolar disorder, depressive episodes are more common and impairing, with few proven treatments. Adjunctive therapy with second-generation antidepressants is widely used to treat acute bipolar depression, but their efficacy and safety remain controversial. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception to Jan 31, 2016, for randomised, double-blind, placebo-controlled trials of second-generation antidepressants adjunctive to a mood stabiliser or an antipsychotic in patients with acute bipolar depression...
December 2016: Lancet Psychiatry
https://www.readbyqxmd.com/read/26997707/antipsychotic-trials-in-schizophrenia-from-india-a-systematic-review-and-meta-analysis
#9
S Grover, S Sarkar
Ethnic and regional variations have been found in the pharmacological treatment response. Though many efficacy studies have been conducted in India for antipsychotic treatment modalities of schizophrenia, there is a lack meta-analytic data of the existing literature from India. This study aimed to conduct a systematic review and meta-analysis of the antipsychotic treatment trials of schizophrenia in the Indian context. All controlled trials from India evaluating the clinical efficacy of antipsychotics in patients with schizophrenia were evaluated and 28 trials were included in the metanalysis...
November 2015: Indian Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/26842482/efficacy-acceptability-and-tolerability-of-antipsychotics-in-treatment-resistant-schizophrenia-a-network-meta-analysis
#10
Myrto T Samara, Markus Dold, Myrsini Gianatsi, Adriani Nikolakopoulou, Bartosz Helfer, Georgia Salanti, Stefan Leucht
IMPORTANCE: In treatment-resistant schizophrenia, clozapine is considered the standard treatment. However, clozapine use has restrictions owing to its many adverse effects. Moreover, an increasing number of randomized clinical trials (RCTs) of other antipsychotics have been published. OBJECTIVE: To integrate all the randomized evidence from the available antipsychotics used for treatment-resistant schizophrenia by performing a network meta-analysis. DATA SOURCES: MEDLINE, EMBASE, Biosis, PsycINFO, PubMed, Cochrane Central Register of Controlled Trials, World Health Organization International Trial Registry, and clinicaltrials...
March 2016: JAMA Psychiatry
https://www.readbyqxmd.com/read/26557987/mirtazapine-for-antipsychotic-induced-acute-akathisia-a-systematic-review-and-meta-analysis-of-randomized-placebo-controlled-trials
#11
REVIEW
Samir Kumar Praharaj, Sreejayan Kongasseri, Rishikesh V Behere, Podila Satya Venkata Narasimha Sharma
OBJECTIVE: To conduct a systematic review and meta-analysis of randomized placebo-controlled trials of mirtazapine for the treatment of antipsychotic-induced acute akathisia (AIAA). METHODS: Studies were identified using online searches of PUBMED/MEDLINE and Cochrane database (CENTRAL), along with websites recording trial information such as www.clinicaltrials.gov, www.controlled-trials.com, and www.clinicalstudyresults.org. The study eligibility criteria were randomized, double-blind clinical trials comparing mirtazapine with placebo for AIAA with standardized rating for akathisia as outcome measure...
October 2015: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/26554370/a-meta-analysis-of-placebo-controlled-trials-of-omega-3-fatty-acid-augmentation-in-schizophrenia-possible-stage-specific-effects
#12
Alexander T Chen, John T Chibnall, Henry A Nasrallah
BACKGROUND: Omega-3 fatty acids have shown promise as an adjunctive treatment for schizophrenia. However, efficacy across studies has been inconsistent. We conducted a meta-analysis of published controlled studies with the goal of detecting different efficacy profiles at various stages of schizophrenia. METHODS: An online search was conducted for randomized, double-blind, placebo-controlled clinical trials, and a meta-analysis was conducted. RESULTS: Ten studies met the criteria for inclusion...
November 2015: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/26341326/antipsychotic-medications-for-the-treatment-of-delirium-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials
#13
REVIEW
Taro Kishi, Tomoya Hirota, Shinji Matsunaga, Nakao Iwata
OBJECTIVES: We performed an updated meta-analysis of antipsychotic treatment in patients with delirium, based on a previous meta-analysis published in 2007. METHODS: Included in this study were randomised, placebo-controlled or usual care (UC) controlled trials of antipsychotics in adult patients with delirium. Our primary outcome measure was response rate at the study end point. The secondary outcome measures included improvement of severity of delirium, Clinical Global Impression-Severity Scale (CGI-S), time to response (TTR), discontinuation rate and individual adverse effects...
July 2016: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/25321611/placebo-response-in-antipsychotic-clinical-trials-a-meta-analysis
#14
Bret R Rutherford, Emily Pott, Jane M Tandler, Melanie M Wall, Steven P Roose, Jeffrey A Lieberman
IMPORTANCE: Because increasing placebo response rates decrease drug-placebo differences and increase the number of failed trials, it is imperative to determine what is causing this trend. OBJECTIVES: To investigate the relationship between antipsychotic medication and placebo response by publication year, and to identify associated study design and implementation variables. DATA SOURCES: MEDLINE, PsycINFO, and PubMed were searched to identify randomized clinical trials of antipsychotic medications published from 1960 to July 2013...
December 1, 2014: JAMA Psychiatry
https://www.readbyqxmd.com/read/24882700/the-potential-role-of-atypical-antipsychotics-for-the-treatment-of-posttraumatic-stress-disorder
#15
REVIEW
Changsu Han, Chi-Un Pae, Sheng-Min Wang, Soo-Jung Lee, Ashwin A Patkar, Praksh S Masand, Alssandro Serretti
Despite the fact that the majority of currently available treatment guidelines propose antidepressants as the first-line pharmacological therapy for posttraumatic stress disorder (PTSD), a substantial portion of patients fail to show an adequate response following this type of treatment. In this context, a number of small, open-label studies and randomized controlled clinical trials (RCTs) have found atypical antipsychotics (AAs) to be a beneficial treatment for patients with PTSD. Thus, the present meta-analysis was conducted to enhance the sample size power and further the current understanding of the role of AAs for the treatment of PTSD...
September 2014: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/24729184/sulpiride-versus-placebo-for-schizophrenia
#16
REVIEW
Jijun Wang, Stephanie Sampson
BACKGROUND: Sulpiride is a relatively old antipsychotic drug reputed to have a low incidence of adverse effects and an effect on the negative symptoms of schizophrenia. This relatively inexpensive antipsychotic drug has a similar neuropharmacological profile to several novel atypical drugs. OBJECTIVES: To evaluate the effects of sulpiride for schizophrenia and other similar serious mental illnesses in comparison with placebo. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (September 2008) and references of all identified studies for further trial citations...
2014: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/24284258/lithium-or-an-atypical-antipsychotic-drug-in-the-management-of-treatment-resistant-depression-a-systematic-review-and-economic-evaluation
#17
REVIEW
S J Edwards, V Hamilton, L Nherera, N Trevor
BACKGROUND: Patients with treatment-resistant depression (TRD) are those with major depressive disorder that has not responded adequately to treatment. The causes of depression are not fully understood, although there is evidence to suggest that depression is a complex interaction among biological, genetic, psychosocial and environmental factors. Strategies available for the treatment of patients with TRD include pharmacological, non-pharmacological, and psychological and psychosocial interventions...
November 2013: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/23896810/meta-regression-analysis-of-placebo-response-in-antipsychotic-trials-1970-2010
#18
Ofer Agid, Cynthia O Siu, Steven G Potkin, Shitij Kapur, Eric Watsky, Douglas Vanderburg, Robert B Zipursky, Gary Remington
OBJECTIVE: Large placebo response presents a major challenge for psychopharmacologic drug development and contributes to the increasing failure of psychiatric trials. The objective of this meta-regression analysis was to identify potential contributors to placebo response in randomized controlled trials of antipsychotic treatment in schizophrenia. METHOD: The authors extracted trial design and clinical variables from eligible randomized controlled trials (N=50) identified through searches of MEDLINE (1960-2010) and other sources...
November 2013: American Journal of Psychiatry
https://www.readbyqxmd.com/read/23554581/adjunctive-atypical-antipsychotic-treatment-for-major-depressive-disorder-a-meta-analysis-of-depression-quality-of-life-and-safety-outcomes
#19
Glen I Spielmans, Margit I Berman, Eftihia Linardatos, Nicholas Z Rosenlicht, Angela Perry, Alexander C Tsai
BACKGROUND: Atypical antipsychotic medications are widely prescribed for the adjunctive treatment of depression, yet their total risk-benefit profile is not well understood. We thus conducted a systematic review of the efficacy and safety profiles of atypical antipsychotic medications used for the adjunctive treatment of depression. METHODS AND FINDINGS: We included randomized trials comparing adjunctive antipsychotic medication to placebo for treatment-resistant depression in adults...
2013: PLoS Medicine
https://www.readbyqxmd.com/read/23290326/meta-analyses-of-the-efficacy-of-asenapine-for-acute-schizophrenia-comparisons-with-placebo-and-other-antipsychotics
#20
COMPARATIVE STUDY
Armin Szegedi, Pierre Verweij, Wilbert van Duijnhoven, Mary Mackle, Pilar Cazorla, Hein Fennema
CONTEXT: Asenapine is an approved treatment for schizophrenia in the United States. OBJECTIVE: Meta-analyses were conducted to evaluate the efficacy of asenapine in acute schizophrenia compared with placebo and other antipsychotics. DATA SOURCES: Four asenapine trials from the asenapine development program were pooled for the meta-analysis. To compare asenapine versus placebo treatment effect with other antipsychotics, we added integrated asenapine data to a previously published meta-analysis...
December 2012: Journal of Clinical Psychiatry
keyword
keyword
41464
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"